Table 1.

Primary and secondary endpoints in the EGeSOR trial

Endpoints	Time assessed	Description
Primary endpoint	6 months after randomisation	Composite criterion including
		- death,
		- at least 2-point decrease in the Activities of Daily Living (ADL) score versus baseline
		- at least 10% decrease in body weight versus baseline
Secondary endpoints	6, 12, and 24 months after randomisation	- each component of the primary endpoint
		- progression-free survival
		- in-hospital death
		- unplanned admissions
		- post-surgery hospital stay length
		- discharge to home or nursing home
		- final cancer treatment plan (surgery, chemotherapy, targeted therapies, radiotherapy, and/or supportive care, alone or combined)
		- quality of life assessed by EORTC QLQ-C30 and specific module for head and neck cancer H&N35
		- treatment toxicities and/or complications: chemotherapy toxicities according to Classification Common Terminology Criteria for Adverse Events (CTCAE version 4.02)
		- cancer treatment feasibility
		- costs